Osteoporosis - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 263
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O01E16645AEEN
Leaflet:

Download PDF Leaflet

Osteoporosis - Pipeline Review, H2 2017
Osteoporosis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H2 2017, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 5, 5, 13, 1, 55 and 13 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 14 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Osteoporosis - Overview
Osteoporosis - Therapeutics Development
Osteoporosis - Therapeutics Assessment
Osteoporosis - Companies Involved in Therapeutics Development
Osteoporosis - Drug Profiles
Osteoporosis - Dormant Projects
Osteoporosis - Discontinued Products
Osteoporosis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Osteoporosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Osteoporosis - Pipeline by Abreos Biosciences Inc, H2 2017
Osteoporosis - Pipeline by Alize Pharma SAS, H2 2017
Osteoporosis - Pipeline by Alvogen Korea Co Ltd, H2 2017
Osteoporosis - Pipeline by Amgen Inc, H2 2017
Osteoporosis - Pipeline by Amura Holdings Ltd, H2 2017
Osteoporosis - Pipeline by BiologicsMD Inc, H2 2017
Osteoporosis - Pipeline by Bone Biologics Corp, H2 2017
Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H2 2017
Osteoporosis - Pipeline by Cadila Healthcare Ltd, H2 2017
Osteoporosis - Pipeline by Cellmid Ltd, H2 2017
Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H2 2017
Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Osteoporosis - Pipeline by Corium International Inc, H2 2017
Osteoporosis - Pipeline by Critical Pharmaceuticals Ltd, H2 2017
Osteoporosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Osteoporosis - Pipeline by ElexoPharm GmbH, H2 2017
Osteoporosis - Pipeline by EndoCeutics Inc, H2 2017
Osteoporosis - Pipeline by Entera Bio Ltd, H2 2017
Osteoporosis - Pipeline by Enteris BioPharma Inc, H2 2017
Osteoporosis - Pipeline by Enzene Biosciences Ltd, H2 2017
Osteoporosis - Pipeline by Enzo Biochem Inc, H2 2017
Osteoporosis - Pipeline by Evgen Pharma Plc, H2 2017
Osteoporosis - Pipeline by Gador SA, H2 2017
Osteoporosis - Pipeline by GL Pharm Tech Corp, H2 2017
Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Osteoporosis - Pipeline by Haoma Medica Ltd, H2 2017
Osteoporosis - Pipeline by Immunovo BV, H2 2017
Osteoporosis - Pipeline by Immunwork Inc, H2 2017
Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H2 2017
Osteoporosis - Pipeline by Ipsen SA, H2 2017
Osteoporosis - Pipeline by Kaken Pharmaceutical Co Ltd, H2 2017
Osteoporosis - Pipeline by Lead Discovery Center GmbH, H2 2017
Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017
Osteoporosis - Pipeline by Lupin Ltd, H2 2017
Osteoporosis - Pipeline by Luye Pharma Group Ltd, H2 2017
Osteoporosis - Pipeline by mAbxience SA, H2 2017
Osteoporosis - Pipeline by Merck & Co Inc, H2 2017
Osteoporosis - Pipeline by Mereo Biopharma Group Plc, H2 2017
Osteoporosis - Pipeline by NIBEC, H2 2017
Osteoporosis - Pipeline by Omeros Corp, H2 2017
Osteoporosis - Pipeline by Oncobiologics Inc, H2 2017
Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017
Osteoporosis - Pipeline by Pfenex Inc, H2 2017
Osteoporosis - Pipeline by PhytoHealth Corp, H2 2017
Osteoporosis - Pipeline by R Pharm, H2 2017
Osteoporosis - Pipeline by Ribomic Inc, H2 2017
Osteoporosis - Pipeline by Sermonix Pharmaceuticals LLC, H2 2017
Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017
Osteoporosis - Pipeline by Shin Poong PharmCo Ltd, H2 2017
Osteoporosis - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017
Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H2 2017
Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H2 2017
Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H2 2017
Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H2 2017
Osteoporosis - Pipeline by Viking Therapeutics Inc, H2 2017
Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H2 2017
Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H2 2017
Osteoporosis - Dormant Projects, H2 2017
Osteoporosis - Dormant Projects, H2 2017 (Contd.1), H2 2017
Osteoporosis - Dormant Projects, H2 2017 (Contd.2), H2 2017
Osteoporosis - Dormant Projects, H2 2017 (Contd.3), H2 2017
Osteoporosis - Dormant Projects, H2 2017 (Contd.4), H2 2017
Osteoporosis - Dormant Projects, H2 2017 (Contd.5), H2 2017
Osteoporosis - Dormant Projects, H2 2017 (Contd.6), H2 2017
Osteoporosis - Dormant Projects, H2 2017 (Contd.7), H2 2017
Osteoporosis - Discontinued Products, H2 2017
Osteoporosis - Discontinued Products, H2 2017 (Contd.1), H2 2017

LIST OF FIGURES

Number of Products under Development for Osteoporosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Abreos Biosciences Inc
Alize Pharma SAS
Alvogen Korea Co Ltd
Amgen Inc
Amura Holdings Ltd
BiologicsMD Inc
Bone Biologics Corp
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Cellmid Ltd
ChoDang Pharm Co Ltd
Chugai Pharmaceutical Co Ltd
Corium International Inc
Critical Pharmaceuticals Ltd
Daiichi Sankyo Co Ltd
ElexoPharm GmbH
EndoCeutics Inc
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Evgen Pharma Plc
Gador SA
GL Pharm Tech Corp
Hanmi Pharmaceuticals Co Ltd
Haoma Medica Ltd
Immunovo BV
Immunwork Inc
Intas Pharmaceuticals Ltd
Ipsen SA
Kaken Pharmaceutical Co Ltd
Lead Discovery Center GmbH
Lotus Pharmaceutical Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
mAbxience SA
Merck & Co Inc
Mereo Biopharma Group Plc
NIBEC
Omeros Corp
Oncobiologics Inc
Paras Biopharmaceuticals Finland Oy
Pfenex Inc
PhytoHealth Corp
R Pharm
Ribomic Inc
Sermonix Pharmaceuticals LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shin Poong PharmCo Ltd
Sinil Pharmaceutical Co Ltd
Stelis Biopharma Pvt Ltd
Sumitomo Dainippon Pharma Co Ltd
Terpenoid Therapeutics Inc
TSH Biopharm Corporation Ltd
Uni-Bio Science Group Ltd
Viking Therapeutics Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Yooyoung Pharm Co Ltd
Skip to top


Post Menopausal Osteoporosis - Pipeline Review, H2 2017 US$ 2,000.00 Oct, 2017 · 86 pages
iCeutica, Inc. - Product Pipeline Review - 2015 US$ 1,500.00 Jul, 2015 · 31 pages

Ask Your Question

Osteoporosis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: